幽门螺杆菌（H. pylori）是一种广泛存在的细菌病原体，与多种胃肠道疾病（包括胃癌）有关。他汀类药物是广泛使用的降胆固醇药物，已证明具有多效性，包括潜在的抗菌特性。这项体外研究调查了三种临床批准的他汀类药物（辛伐他汀、阿托伐他汀和瑞舒伐他汀）对幽门螺杆菌分离株的直接抗菌作用。幽门螺杆菌菌株是从消化不良患者的胃活检中分离出来的，并通过微生物技术进行鉴定。采用琼脂稀释法测定他汀类药物的最低抑菌浓度（MIC），采用纸片扩散法评价不同浓度辛伐他汀、阿托伐他汀、瑞舒伐他汀、四环素和阿莫西林的抗菌活性。采用扫描电镜（SEM）观察H. pylori细胞形态。阿托伐他汀、瑞舒伐他汀、辛伐他汀、四环素、阿莫西林对H. pylori的最低抑菌浓度（MIC）值（μg/mL）均为240±20 、 450±20、460±15、155±30 和 140±20。在纸片扩散测定中，与辛伐他汀相比，阿托伐他汀和瑞舒伐他汀在所有测试浓度下均产生显着更大的抑制区（p < 0.05）。抑制区直径（mm）随着他汀浓度的升高而增大，在最高测试浓度下，阿托伐他汀为9±±1.4～13±1.4，瑞舒伐他汀为8±±0.9～11±0.6，辛伐他汀为5±±1.3～6±1.4 （1200μg/ml）。 SEM 分析揭示了幽门螺杆菌细胞的特征性螺旋形态。他汀类药物对幽门螺杆菌分离株表现出不同程度的抗菌活性，其中阿托伐他汀表现出最高的效力。虽然观察到的效果低于传统抗生素，但这些发现表明他汀类药物作为辅助药物或替代治疗选择的潜力，值得通过体内研究和临床试验进行进一步研究。版权所有 © 2024 Manijeh Ebrahimzadeh 等人。

Helicobacter pylori (H. pylori), a widespread bacterial pathogen, is associated with various gastrointestinal diseases, including gastric cancer. Statins, widely prescribed cholesterol-lowering agents, have demonstrated pleiotropic effects, including potential antimicrobial properties. This in vitro study investigated the direct antibacterial effects of three clinically approved statins, simvastatin, atorvastatin, and rosuvastatin, against H. pylori isolates.H. pylori strains were isolated from gastric biopsies of dyspeptic patients and identified by microbiological techniques. The minimum inhibitory concentrations (MICs) of statins were determined using the agar dilution method, and their antimicrobial activity was evaluated by the disc diffusion method using different concentrations of simvastatin, atorvastatin, rosuvastatin, tetracycline, and amoxicillin. Scanning electron microscopy (SEM) was employed to examine the morphology of H. pylori cells.The minimum inhibitory concentration (MIC) values (μg/mL) of atorvastatin, rosuvastatin, simvastatin, tetracycline, and amoxicillin against H. pylori were 240 ± 20, 450 ± 20, 460 ± 15, 155 ± 30, and 140 ± 20, respectively. In the disc diffusion assay, atorvastatin and rosuvastatin produced significantly larger inhibition zones compared to simvastatin at all concentrations tested (p < 0.05). The inhibition zone diameters (mm) increased with higher statin concentrations, ranging from 9 ± 1.4 to 13 ± 1.4 for atorvastatin, 8 ± 0.9 to 11 ± 0.6 for rosuvastatin, and 5 ± 1.3 to 6 ± 1.4 for simvastatin at the highest tested concentration (1200 μg/ml). SEM analysis revealed the characteristic spiral morphology of H. pylori cells.Statins demonstrated varying degrees of antibacterial activity against H. pylori isolates, with atorvastatin exhibiting the highest potency. While the observed effects were lower than those of conventional antibiotics, these findings suggest the potential of statins as adjunctive agents or alternative therapeutic options, warranting further investigation through in vivo studies and clinical trials.Copyright © 2024 Manijeh Ebrahimzadeh et al.